Andrew Fesnak, MD
Assistant Professor of Clinical Pathology and Laboratory MedicinePerelman School of Medicine at the University of Pennsylvania
Contact InformationHospital of the University of Pennsylvania
3400 Spruce Street
3 Ravdin Building - R3067
Philadelphia, PA 19104
Office: 215-662-3325
Email: fesnak@pennmedicine.upenn.edu
Specialty Division
Transfusion Medicine & Therapeutic Pathology
Education
BA (Molecular Biology), Princeton University, 2005
MD (Medical Doctorate), University of Medicine and Dentistry of New Jersey - Robert Wood Johnson School of Medicine, 2011
MHI (Masters of Health Care Innovation), University of Pennsylvania, 2019
Specialty Certification
Clinical Pathology, American Board of Pathology, 2014
Blood Banking / Transfusion Medicine, American Board of Pathology, 2015
Laboratory Management, Laboratory Management University, American Society for Clinical Pathology, 2015
Postgraduate Training
Resident, Clinical pathology, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2011-2014
Research fellow, Immunology, Kambayashi Lab, Perelman School of Medicine, University of Pennsylvania, 2012-2015
Clinical fellow, Transfusion medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, University of Pennsylvania, 2014-2015
Clinical fellow, Cell therapy, Clinical Cell and Vaccine Production Facility, Perelman School of Medicine, University of Pennsylvania, 2015-2016
Awards and Honors
Inductee, Gold Humanism Honor Society, 2011
The Kevin E. Salhany, MD Award for Excellence in Clinical Teaching, Department of Pathology and Laboratory Medicine Penn Medicine, 2016
Power of A Gold Award - AABB Cellular Therapies Certificate Program, American Society of Association Executives, 2019
SITC Team Science Award - Advanced T cell Engineering Against Malignancies (A-TEAM) team, Society for Immunotherapy of Cancer, 2020
The Simon Flexner Award for Contribution to Graduate Education, Department of Pathology and Laboratory Medicine, PSOM, 2022
Memberships and Professional Organizations
College of American Pathologists (CAP), 2011 - 2013
Association for the Advancement of Blood and Biotherapies (AABB), 2011 - Present
International Society for Cellular Therapy (ISCT), 2011 - Present
American Society for Clinical Pathology (ASCP), 2011 - Present
TerumoBCT, 2017 - 2017
Foundation for the Accreditation of Cellular Therapy (FACT), 2018 - 2021
American Society for Apheresis (ASFA), 2018 - Present
National Heart, Blood and Lung Institute (NHLBI), 2019 - 2019
Vineti Clinical Advisory Board, 2021 - 2021
Web Links
Selected Publications
Adverse Events of Cellular and Biotherapies
Fesnak AD, Raval JS, AABB Technical Manual, 21st edition (in press)(): , 2023
Chimeric antigen receptor T cells and other cellular immunotherapies
Fesnak AD, Siegel DL, Rossi's Principles of Transfusion Medicine, Sixth Edition, 2022
How do I: Evaluate the safety and legitimacy of unproven cellular therapies?
Guleria I, de Los Angeles Muñiz M, Wilgo M, Bapat A, Cui W, Hsu YS, Jeyaraman M, Muthu S, Rodriguez F, Fesnak A, Celluzzi C, Sesok-Pizzini D, Reich-Slotky R, Spitzer T., Transfusion 62(3): 518-532, 2022, PMID:35143051
CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL
Frey NV, Gill S, Hwang WT, Luger SM, Martin ME, McCurdy, SR, Loren AW, Pratz KW, Perl AE, Barber-Rotenberg J, Marshall A, Ruella M, Lacey SF, Fraietta J Fesnak A, O'brien M, Schanne T, Brogdon JL, Engels B, Levine BL, June CH, Porter DL, Hexner EO, Blood 138(Supplement 1): 469, 2021
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia
Bar KJ, Shaw PA, Choi GH, Aqui N, Fesnak A, Yang JB, Soto-Calderon H, Grajales L, Starr, J, Andronov M, Mastellone M, Amonu C, Feret G, DeMarshall M, Buchanan M, Caturla M, Gordon J, Wanicur A, Monroy MA, Mampe F, Lindemuth E, Gouma S, Mullin AM, Barilla H, Pronina A, Irwin L, Thomas R, Eichinger RA, Demuth F, Luning Prak ET, Pascual JL, Short W, Elovitz MA, Baron J, Meyer NJ, Degnan KO, Frank I, Hensley S, Siegel DL, Tebas P, J Clin Invest 131(24): , 2021, PMID:34788233
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, Getz KD, Brogdon JL, Fesnak AD, Siegel DL, Davis MM, Bartoszek C, Lacey SF, Hexner EO, Chew A, Wertheim GB, Levine BL, June CH, Grupp SA, Maude SL, J Clin Oncol 39(27): 3044-3055, 2021, PMID:34156874
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, SavoldoB, Blood Cancer Discov 2(5): 408-422, 2021, PMID:34568831
Discussion of the requirements, challenges and processing adaptations involved in an academic technology transfer of neo-antigen peptide pulsed peptide pulsed dendritic cells
Brennan AL, Guilliams J, Fox E, Carreno B, Linette G, Levine BL, Plesa G, Siegel D, Mackey S, Fesnak A, Cytotherapy 23(5): S173-S173, 2021
Clinical development of natural killer cells expressing chimeric antigen receptors
Golden RJ, Fesnak AD, Transfus Apher Sci 60(1): 103065, 2021, PMID:33468407
CAR T Cells: A Novel Biological Drug Class
Gladney W, Jadlowsky J, Davis MM, Fesnak A, Successful Drug Discovery, 2021
